In an area that ranks among the highest in the nation for cancer incidence, it is fortunate that more than 100,000 patients each year are served by the Rutgers Cancer Institute of New Jersey (CINJ), the only NCI-designated cancer center in…
By Deb Hickey A new study of U.S. counties found that higher rates of prostate-specific antigen (PSA) screening are linked to lower incidences of advanced or metastatic prostate cancer and reduced prostate cancer mortality rates in subsequent years. USPSTF Recommendation Led to Disastrous Results In 2012, the…
By all accounts, Bob Marckini is remarkably accomplished. Marckini, a registered professional engineer (shown right, with daughter Deb Hickey), is a graduate of the MIT Greater Boston Executive Program and experienced in project engineering, project management, manufacturing management, plant management and division management in the photographic…
A COMPPARE poster abstract has been accepted by the Patient-centered Outcomes Research Institute (PCORI) and will be presented at its 2024 Annual Meeting, which will take place in Washington, D.C., October 22–23. The two-day event brings together patients, caregivers, researchers and the broader healthcare community to learn about…
A Message from Dr. Nancy Mendenhall Over the past two years, we have been searching for funding opportunities to support another 5 years of follow-up for the COMPPARE cohorts to provide all participants with a minimum of 8 years of follow-up. This spring a new funding opportunity was…
Seven years ago, a routine physical for Dan McCarthy yielded an unexpected and unwelcome result: an elevated PSA and a recommendation for a biopsy. Dan and his wife Cindy O’Connell (shown right) couldn’t have been more shocked when the results were positive for prostate cancer. “There is no family history…
ProCure Proton Therapy Center opened its doors in Somerset NJ in March 2012, becoming the tri-state region’s first and longest-established proton therapy facility. Eight years later, in October 2020, the center marked another milestone: a prostate cancer patient became the 5,000th person treated with proton therapy at…
A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…
Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up Questionnaires.
By Bob Marckini Last month, a gentleman told us, sadly, that his father had died from prostate cancer. He then admitted he’d met with his primary care doctor only sporadically over the years and, despite this, didn’t even have regular PSA tests or DREs. Further, he skipped doctors’ visits completely…
